Companies/UK/BP

BP PLC $0.25

Last · LSE£5.145-0.082 (-1.57%)stale · yahoo · 269h ago
Market cap
P/E · TTMfwd · eps
Betavs S&P 500
Div yieldannual · TTM
52w range
Volume65.2Msession

Issuer

Legal nameBP PLC $0.25
HQUnited Kingdom (UK)
ListingLN BP
ISINGB0007980591
SectorEnergy
IndustryOil/Gas (Integrated)
SIC2911
CurrencyUSD
Entity registrylei:213800LH1BZH3DI6G760
Org ID00102498
CIK0000313807
Websitewww.bp.com
LinkedIn
Employees93,700
AddressBP Plc 1 St James's Square Street SW1Y 4PD, London +44 20 7496 4000
Headline financial metrics
Revenue$192.5B
Operating income$12.6B
Net income$55.0M
Operating margin6.6%
Net margin0.0%
Return on equity0.1%
Period2025
Loading chart…

OpenFilings analyst

Our analyst

Agentic read of the latest earnings call — recommendation updates when we process a new transcript. Research synthesis, not investment advice.

Balance-sheet progress is tangible, but operational execution and capital-return visibility remain insufficient for a buy rating.

Latest call · 2026-08-04

Hold.

BP delivered a stronger quarter with net debt down $3 billion sequentially and total financial obligations targeted at $39–41 billion by year-end, but the investment case remains execution-dependent. Reliability fell to 92.4% upstream and 94.7% in refining, cost reductions have not yet reached earnings, and management still offered no framework for buybacks or enhanced shareholder returns.

Themes
  • Balance Sheet
  • Deleveraging
  • Operational Reliability
  • Cost Reduction
  • Portfolio Simplification
  • Bpx Growth
+2

Near term

Investors will focus on delivery against the $39–41 billion year-end total financial-obligations target and the pace of hybrid redemptions, including $1 billion in Q3 and $1.4 billion in Q2 2027.

Operational reliability must recover after North Sea, Indonesia and Whiting-related disruptions reduced upstream and refining availability.

Second-half capex is higher because the planned Paleogene farm-down was deferred; asset-sale timing and proceeds will remain important for deleveraging.

Gas-trading performance could benefit if European and international gas volatility increases, but management gave no forward trading guidance.

Longer term

Management is repositioning BP around assets that can compete in its actual scale, rather than maintaining a supermajor posture; this may improve capital discipline but highlights BP's relative size disadvantage versus larger peers.

The cost base is targeted at approximately $18 billion by 2027 versus $22 billion in 2025, but the key test is whether savings translate into earnings and cash flow rather than merely structural reductions.

bpx is a potentially attractive growth engine, with Q2 production of 545 thousand boe/d and short-cycle capital advantages across the Permian, Eagle Ford and Haynesville.

Paleogene developments Kaskida and Tiber-Guyana are expected to commercialise more than 600 million barrels, but delayed farm-downs increase BP's near-term capital burden and execution exposure.

Bumerangue in Brazil, Kirkuk in the Middle East and US upstream assets provide growth options, though Bumerangue still requires appraisal data before its commercial quality is clear.

Portfolio simplification could ultimately improve returns, but BP's smaller scale and history of impairments remain structural risks to its competitive position and capital-allocation credibility.

Red flags

Upstream reliability dropped to 92.4% and refining availability to 94.7%; management acknowledged that performance fell short and cited multiple operational failures rather than a single isolated event.

Management conceded that cost reductions are not flowing through fast enough to the bottom line and are currently being offset by inflation, foreign exchange, environment and activity choices.

BP has not yet defined the future capital-allocation framework, including buybacks or shareholder distributions above the 4% minimum dividend increase; approximately $40 billion of liabilities is still viewed as too high.

No major upstream FID is expected in 2026, pointing to a quieter investment pipeline while the company reviews its portfolio and capital requirements.

Management continues to acknowledge a history of excessive impairments and wasted shareholder capital, with no quantified hurdle rates or specific safeguards disclosed on the call.

The deferred Paleogene farm-down raises capex and balance-sheet exposure; management prioritised price and partner quality but did not quantify the additional capital burden or timing.

OpenFilings analyst view from primary-source filings and earnings calls — not investment advice.

From latest 20-F · 2023-03-10

  • Net Margin Sharply Negative

Red flags

  • Net Margin Sharply Negative — Net margin -109.4%

Earnings transcripts

3 recent

Press & signals

3 of 12 recent
  • Satelight

    Fantasy M&A: the recipe for a European champion

  • Satelight

    ‘SmashCos’: Europe’s oil majors create new generation of independent companies

  • Satelight

    BP joins Big Oil return to post-Maduro Venezuela

The rest of this company's wire — with summaries and source links — is part of Pro.

See plans

Documents

FormReporting forFiledFlags
2026-09-030
2026-09-010
2026-08-040
2026-06-302026-08-040